Sol gel Technologies Ltd (SLGL) - News Archive

Showing 4 of 4 results.

Sol-Gel Secures Exclusive Licensing Agreements for TWYNEO and EPSOLAY in Europe and South Africa

Sol-Gel Technologies, an innovative pharmaceutical company, has recently announced the signing of six exclusive license agreements aimed at the commercialization of its dermatological products, TWYNEO and EPSOLAY, in Eu...

Jul 25, 2024 • Major Pharmaceutical Preparations Industry Licensing Agreement dermatology

Sol-Gel and Beimei Pharma Join Forces to Uphold Acne Treatment in China, Hong Kong, Macau, Taiwan, and Israel with TWYNEO

TWYNEO, developed by Sol-Gel, is a novel fixed-dose combination therapy for acne vulgaris. It combines minocycline, one of the most widely prescribed oral antibiotics for acne, with Sol-Gel s proprietary 5% benzoyl pero...

May 16, 2024 • Major Pharmaceutical Preparations Industry Product Service News dermatology

Sol-Gels Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream: A Potential Game-Changer in Dermatological Treatments

The pharmaceutical industry continues to witness groundbreaking advancements that change the landscape of medical treatments. In an exciting development, Sol-Gels Collaboration Partner has emerged as the first to file a...

Apr 1, 2024 • Major Pharmaceutical Preparations Industry Partnership dermatology

Sol-Gel Technologies Takes on Gorlin Syndrome with Potential Paradigm-Shifting Treatment SGT-610

Sol-Gel Technologies Begins Phase 3 Study for SGT-610, a Potential Groundbreaking Treatment for Gorlin SyndromeNESS ZIONA, Israel, Nov. 30, 2023 - Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a renowned dermatology compan...

Nov 30, 2023 Clinical Study